TP53 and non-small cell lung carcinoma: Our analysis also shows that the TP53 gene is mutated in over 50% NSCLC patients, with truncating mutations in the TP53 gene accounting for 19.1% and 13.5% among the patients in the MSK-IMPACT- and MSK-NSCLC cohorts, respectively.